Pfizer Inc is not in talks with Chinese authorities to license a generic version of its COVID-19 treatment Paxlovid for use there, but is in discussions about a price for the branded product, Chief Executive Albert Bourla said on Monday.
is not in talks with Chinese authorities to license a generic version of its COVID-19 treatment Paxlovid for use there, but is in discussions about a price for the branded product, Chief Executive Albert Bourla said on Monday.that China was in talks with Pfizer to secure a license that will allow domestic drugmakers to manufacture and distribute a generic version of the U.S. firm's COVID-19 antiviral drug Paxlovid in China.
in an update to its list of medicines covered by basic medical insurance schemes as the U.S. firm quoted a high price for the COVID-19 drug. "They are the second highest economy in the world and I don't think that they should pay less than El Salvador," Bourla said. The failure of the talks to include Pfizer in the list of medicines covered by basic state health insurance generated heated discussions on Chinese social media on Monday.
Pfizer declined to comment on the Chinese media reports about the price it quoted during the negotiations. NHSA did not immediately reply to a Reuters request for comment on the negotiations. "If they do care about it , why don't Pfizer drop some pursuit of the profit, and cooperate with China with a little more sincerity?"
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer CEO says there will be no generic Paxlovid for ChinaPfizer Inc is not in talks with Chinese authorities to license a generic version of its COVID-19 treatment Paxlovid for use there, but is in discussions about a price for the branded product, Chief Executive Albert Bourla said on Monday.
Read more »
Pfizer working to send COVID pill Paxlovid to China - CNBCPfizer Inc is working with Chinese authorities to send its COVID-19 pill, Paxlovid, to the country that is dealing with a surge in COVID-19 cases, Chief Executive Officer Albert Bourla said in an interview with CNBC on Monday.
Read more »
Pfizer's Paxlovid not included in China's national insuranceTAIPEI, Taiwan (AP) — Chinese health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive.
Read more »
Twitter Files: Pfizer board member Dr. Scott Gottlieb flagged tweets questioning COVID vaccineAlex Berenson was the latest writer to be tapped by Elon Musk to dive into Twitter's archives, showing Dr. Scott Gottlieb, a Pfizer board member, targeting vaccine skepticism.
Read more »
China says talks to include Paxlovid in state health insurance failChina's Health Security Administration said on Sunday that talks to include Pfizer's Paxlovid in the latest drug list for basic state health insurance did not succeed.
Read more »
China says talks to include Paxlovid in its insurance drug list failChina will not include Pfizer Inc's Paxlovid in an update to its list of medicines covered by basic medical insurance schemes as the U.S. firm quoted a high price for the COVID-19 drug, China's Healthcare Security Administration (NHSA) said on Sunday.
Read more »